Robust In Vivo Synergy Between the Anti-CD33 ADC IMGN779 and the FLT3 Inhibitor Quizartinib in Human FLT3-ITD AML Models
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.